substance p has been researched along with Cutaneous T-Cell Lymphoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duvic, M; Huang, S; Lewis, DJ | 1 |
| Chau, NG; Kupper, TS; LeBoeuf, NR; Song, JS; Tawa, M | 1 |
| Bazakas, A; Ladizinski, B; Olsen, EA | 1 |
2 review(s) available for substance p and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T-cell lymphoma.
Topics: Analgesics, Opioid; Histamine; Humans; Interleukins; Lymphoma, T-Cell, Cutaneous; Nerve Growth Factor; Nicotinamide Phosphoribosyltransferase; Pruritus; Substance P | 2018 |
Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
Topics: Adult; Aged; Aprepitant; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Protein Binding; Pruritus; Substance P | 2017 |
1 other study(ies) available for substance p and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma.
Topics: Aged; Antipruritics; Aprepitant; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Morpholines; Neurokinin-1 Receptor Antagonists; Ondansetron; Pain Measurement; Recombinant Proteins; Substance P | 2012 |